Skip to main content
    A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $27.87
    -1.17 (-4.03%)

    Market Cap: $4.70B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Adaptive Biotechnologies Corp (ADPT) Government Contracts

    Updated Aug 4, 2026. Contract data from federal award records.

    Federal agencies obligated $251,000 to Adaptive Biotechnologies over the 12 months through Jul 31, 2026. That is less than 1% of its revenue. Department of Defense was the top awarding agency with 50.8% of obligations across 2 agencies.

    Federal Obligations

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated.

    Obligations
    $251,000
    Obligations to revenue
    0.1%
    Prior 12 months$239,280
    Contracts with activity9
    New contracts2
    Top agencyDepartment of Defense
    Top agency share50.8%
    Agencies2
    Average remaining term6.4 months

    12 months through Jul 31, 2026

    Largest New Awards

    The 2 largest new awards total $278,850, and the largest makes up 87.4% of that.

    Award IDAgencyAmountStartEndDescription
    36C25026P0251Department of Veterans Affairs$243,750Dec 29, 2025Dec 28, 2026CLONO-SEQ TESTING.
    36C24126N0614Department of Veterans Affairs$35,100Jul 15, 2026Jul 14, 2027CLONOSEQ TESTING FOR BOSTON AND WEST HAVEN VA HCS
    New federal contracts awarded in the 12 months through Jul 31, 2026, largest first. All from the Department of Veterans Affairs.

    Monthly Obligations

    The latest complete month, Apr 2026, had no net obligations. The largest month in the table was Sep 2024, at $271,870, the last month of the federal fiscal year.

    MonthObligations
    Jul 2026$0
    Jun 2026$0
    May 2026$32,900
    Apr 2026$0
    Mar 2026$0
    Feb 2026$128,700
    Jan 2026-$200
    Dec 2025$243,750
    Nov 2025$0
    Oct 2025-$154,150
    Sep 2025$0
    Aug 2025$0
    MonthObligations
    Jul 2025$0
    Jun 2025$0
    May 2025$16,560
    Apr 2025$95,000
    Mar 2025$117,000
    Feb 2025$44,850
    Jan 2025$0
    Dec 2024-$306,000
    Nov 2024$0
    Oct 2024$0
    Sep 2024$271,870
    Aug 2024$0

    Net obligations recorded each month, newest first. Agencies report contract actions with a delay (the Defense Department about 90 days), so the latest months, May to Jul 2026, are still incomplete and the 12-month total usually rises as agencies report the rest.

    Frequently Asked Questions About ADPT

    How much does Adaptive Biotechnologies receive in federal contracts?

    Adaptive Biotechnologies had $251,000 in federal contract obligations over the 12 months through Jul 31, 2026, compared with $239,280 in the 12 months before. Obligations are contract bookings by the awarding agency, not recognized revenue.

    What are Adaptive Biotechnologies' largest government contracts?

    The largest new awards over the 12 months through Jul 31, 2026 were 36C25026P0251, Department of Veterans Affairs, $243,750, started Dec 29, 2025; 36C24126N0614, Department of Veterans Affairs, $35,100, started Jul 15, 2026.

    Which agencies award Adaptive Biotechnologies contracts?

    Department of Defense was the top awarding agency with 50.8% of obligations over the 12 months through Jul 31, 2026. The records cover 2 agencies. Other agencies in the awards list include Department of Veterans Affairs.

    What new federal contracts did Adaptive Biotechnologies win in the 12 months through Jul 31, 2026?

    Adaptive Biotechnologies won 2 new federal contracts in the 12 months through Jul 31, 2026. The largest was 36C25026P0251, Department of Veterans Affairs, $243,750, started Dec 29, 2025.

    How do Adaptive Biotechnologies' federal obligations compare with its revenue?

    Federal contract obligations were $251,000 over the 12 months through Jul 31, 2026, equivalent to less than 1% of Adaptive Biotechnologies' revenue. Obligations are amounts the government committed to contracts in the period, not the share of Adaptive Biotechnologies' revenue that comes from the government.